Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Viking Therapeutics’s reported figures.
Plus components not separately reported this period.
The source filing: Viking Therapeutics’s 10-Q, filed April 30, 2026. Open the filing →
- Filed
- Apr 29, 2026, 9:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-193315
FAQ
- What is Viking Therapeutics's EBIT?
- Viking Therapeutics (VKTX) reported EBIT of -$164.13M in Q1 2026.
- How has Viking Therapeutics's EBIT changed year-over-year?
- Viking Therapeutics's EBIT decreased by 195.9% year-over-year, from -$55.47M to -$164.13M.
- What is the long-term trend for Viking Therapeutics's EBIT?
- Over 4 years (2021 to 2025), Viking Therapeutics's EBIT has grown at a 63.0% compound annual growth rate (CAGR), from -$55.68M to -$393.34M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Viking Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude